Identification of actin network proteins, talin-1 and filamin-A, in circulating extracellular vesicles as blood biomarkers for human myalgic encephalomyelitis/chronic fatigue syndrome. — CFSMEATLAS
Identification of actin network proteins, talin-1 and filamin-A, in circulating extracellular vesicles as blood biomarkers for human myalgic encephalomyelitis/chronic fatigue syndrome.
Eguchi, Akiko, Fukuda, Sanae, Kuratsune, Hirohiko et al. · Brain, behavior, and immunity · 2020 · DOI
Quick Summary
This study found that people with ME/CFS have higher levels of tiny particles called extracellular vesicles in their blood, which contain specific proteins (talin-1 and filamin-A) that appear to be unique markers of the disease. By measuring these particles and proteins in a simple blood test, researchers were able to correctly identify ME/CFS patients about 90-94% of the time, suggesting this could become a useful diagnostic tool.
Why It Matters
ME/CFS currently lacks objective diagnostic biomarkers, leading to delayed diagnosis and misclassification. This study offers a potential non-invasive blood test that could enable earlier, more accurate diagnosis and help researchers understand the biological mechanisms underlying the disease. Validated biomarkers could improve patient outcomes and facilitate better clinical trial design.
Observed Findings
Circulating EVs were significantly elevated in ME/CFS patients compared to controls and other fatigue/mood disorders
EV elevation correlated with C-reactive protein and biological antioxidant potential
Talin-1, filamin-A, and 14-3-3 family proteins were the most abundant EV-associated proteins in ME/CFS
Proteins identified are involved in focal adhesion, actin cytoskeleton regulation, PI3K-Akt signaling, and EBV infection pathways
Inferred Conclusions
Circulating EVs and their protein cargo represent novel objective biomarkers for ME/CFS diagnosis
Actin network dysfunction and cytoskeletal dysregulation may be central pathogenic mechanisms in ME/CFS
These biomarkers could enable disease stratification and distinguish ME/CFS from other conditions presenting with chronic fatigue or depression
Remaining Questions
Do EV levels and protein composition change with disease progression, remission, or treatment response?
What is the biological mechanism linking actin network dysfunction and the cellular stress responses in ME/CFS?
What This Study Does Not Prove
This study does not establish causation—elevated EVs and these proteins may be consequences of ME/CFS rather than causes. The cross-sectional design cannot determine whether these biomarkers persist throughout illness or change over time. It also does not prove these markers are sufficient for diagnosis in all patients or validate the test's performance in routine clinical practice.